Back to Search
Start Over
Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)
- Source :
- Blood; December 2015, Vol. 126 Issue: 23 p1588-1588, 1p
- Publication Year :
- 2015
-
Abstract
- Levy: ARIAD Pharmaceuticals, Inc: Other: abstract publication value, advisory board speaking engagement, advisory board participation. McGarry:ARIAD: Employment, Equity Ownership. Lustgarten:ARIAD Pharmaceuticals Inc.: Employment, Equity Ownership, Other: Stock. Yang:ARIAD Pharmaceuticals, Inc: Employment. Haluska:ARIAD Pharmaceuticals, Inc.: Employment, Equity Ownership.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 126
- Issue :
- 23
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53082277
- Full Text :
- https://doi.org/10.1182/blood.V126.23.1588.1588